Disease · MONDO_0005494
Comparisons in its trials86
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 86
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Placebo (q2w) + Nab-Paclitaxel vs Atezolizumab (q2w) + Nab-Paclitaxel: deaths from any cause | 333 of 451 | 314 of 451 | 902 | NCT02425891 | Trial comparisons |
| Placebo (q2w) + Nab-Paclitaxel vs Atezolizumab (q2w) + Nab-Paclitaxel: serious adverse events | 80 of 430 | 110 of 460 | 890 | NCT02425891 | Trial comparisons |
| Atezolizumab + Paclitaxel vs Placebo + Paclitaxel: deaths from any cause | 229 of 431 | 119 of 220 | 651 | NCT03125902 | Trial comparisons |
| Atezolizumab + Paclitaxel vs Placebo + Paclitaxel: serious adverse events | 112 of 431 | 40 of 220 | 651 | NCT03125902 | Trial comparisons |
| Placebo + Chemotherapy vs Atezolizumab + Chemotherapy: Number of Participants With Adverse Events (AEs) | 283 of 294 | 281 of 293 | 587 | NCT03371017 | Trial comparisons |
| Placebo + Chemotherapy vs Atezolizumab + Chemotherapy: deaths from any cause | 233 of 294 | 226 of 293 | 587 | NCT03371017 | Trial comparisons |
| Placebo + Chemotherapy vs Atezolizumab + Chemotherapy: serious adverse events | 57 of 294 | 69 of 293 | 587 | NCT03371017 | Trial comparisons |
| Bevacizumab Plus Paclitaxel vs Bevacizumab Plus Capecitabine: deaths from any cause | 196 of 284 | 209 of 277 | 561 | NCT00600340 | Trial comparisons |
| Bevacizumab Plus Paclitaxel vs Bevacizumab Plus Capecitabine: serious adverse events | 65 of 284 | 68 of 277 | 561 | NCT00600340 | Trial comparisons |
| Arm A vs Arm B: Disease Free Survival (DFS) | 15 of 180 | 10 of 179 | 359 | NCT04770272 | Trial comparisons |
| Arm A vs Arm B: Event Free Survival (EFS) | 20 of 180 | 16 of 179 | 359 | NCT04770272 | Trial comparisons |
| Arm A vs Arm B: Overall Survival (OS). | 5 of 180 | 3 of 179 | 359 | NCT04770272 | Trial comparisons |
| Arm A vs Arm B: deaths from any cause | 1 of 180 | 0 of 179 | 359 | NCT04770272 | Trial comparisons |
| Arm A vs Arm B: serious adverse events | 86 of 178 | 87 of 178 | 356 | NCT04770272 | Trial comparisons |
| Placebo and Chemotherapy vs Atezolizumab and Chemotherapy: deaths from any cause | 28 of 167 | 16 of 164 | 331 | NCT03197935 | Trial comparisons |
| Placebo and Chemotherapy vs Atezolizumab and Chemotherapy: serious adverse events | 36 of 167 | 59 of 164 | 331 | NCT03197935 | Trial comparisons |
| Capecitabine vs CDX-011: deaths from any cause | 65 of 92 | 134 of 213 | 305 | NCT01997333 | Trial comparisons |
| Capecitabine vs CDX-011: serious adverse events | 19 of 92 | 71 of 213 | 305 | NCT01997333 | Trial comparisons |
| Pembrolizumab + Olaparib vs Pembrolizumab + Carboplatin + Gemcitabine: Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE) | 15 of 135 | 28 of 133 | 268 | NCT04191135 | Trial comparisons |
| Pembrolizumab + Olaparib vs Pembrolizumab + Carboplatin + Gemcitabine: Number of Participants Who Experienced At Least One Adverse Event (AE) | 126 of 135 | 130 of 133 | 268 | NCT04191135 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005494/comparisons